

⑫

EUROPEAN PATENT APPLICATION

②① Application number: 84200182.8

⑤① Int. Cl.³: **A 61 K 31/13**

②② Date of filing: 09.02.84

BLANK COPY

③① Priority: 15.02.83 IT 1960083

④③ Date of publication of application:
19.09.84 Bulletin 84/38

⑧④ Designated Contracting States:
BE CH DE FR GB IT LI LU NL SE

⑦① Applicant: **Simes S.p.A.**
Via Bellerio 41
I-20161 Milano(IT)

⑦② Inventor: **Virno, Michele**
Via Papiniano 29
I-00137(IT)

⑦④ Representative: **Marchi, Massimo et al,**
c/o CON.P.I. Corso Buenos Aires, 64
I-20124 Milano(IT)

⑤④ **Pharmaceutical compositions and their use in the treatment of glaucoma.**

⑤⑦ **New pharmaceutical compositions and their use in the treatment of glaucoma. Said compositions contain 1-moprolol as active ingredient.**

EP 0 118 940 A1

0118940

"PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF
GLAUCOMA"

5 This invention relates to new pharmaceutical compositions and
to their use in the treatment of glaucoma.

More particularly this invention relates to new pharmaceuti-
cal compositions containing l-moprolol as active ingredient.

10 l-moprolol (LEVOTENSIN[®] - Simes) is a drug useful in the
therapy of arterial hypertension as well as in the treatment and
in the prevention of coronary insufficiency.

Now it has been surprisingly found that l-moprolol shows an
intraocular hypotensive effect equivalent to that of Pilocarpine
and Timolol without causing those side effects and inconve-
niences which are inherent to Pilocarpine (myosis) and to Timo-
15 lol (bradychardia, local anesthesia and tachyphylaxis).

It is known that a drug is able to exert an intraocular hy-
potensive effect when it is vasoactive at the level of ciliary
body in reducing the production of aqueous humour.

20 In addition the drug must be well tolerated locally when
instilled and it must be able to pass through the intraocular
structure to reach the ciliary body. Furthermore, the vascular
properties of the drug must be exerted at local level without
causing any systemic effect.

25 Therefore, the most appropriate tests to evaluate the
intraocular effects of a drug are the followings:

- effect of the drug administered locally on the normal intra-
ocular pressure,
- evaluation of the entity and duration of the intraocular
hypotensive effect of the drug on experimentally induced in-
30 traocular hypertension,

- local tolerability of the drug (biomicroscopy examination of the anterior segment, keratoesthesia, tear secretion: 15 days treatment; observation every 72 hours),
- possible cardiovascular effects after drug instillation,
- 5 - involvement of the ocular circulation in the systemic vascular phenomenon induced by intravenous administration of the drug: examination of the effect on both the systemic arterial pressure and the intraocular pressure recorded constantly and simultaneously,
- 10 - vasomotor activity of the drug on the ciliary body: correlation among vascular activity, vascular permeability and production of aqueous humour,
- comparison of the intraocular hypotensive effect of the drug with respect to the most active anti-glaucoma agents (admini-
- 15 - stered at least after 48 hours one from the other),
- evaluation of the local anesthetic effect "in vitro" on the eye of cat isolated together with a substantial portion of the optical nerve and with the ciliary nerves up to the ciliary ganglion. The system is plunged into a Krebs solution
- 20 and a ciliary nerve branch connected with a recorder. The cornea is submitted to light mechanical percussions and the responses of the ciliary nerve recorded either when the system is plunged into a Krebs solution or into a medicated solution,
- 25 - tachyphylaxis evaluation by administering the drug twice a day for a 30 day period in experimentally induced ocular hypertension and measuring the ocular pressure every two days at different hours.

30 In these tests l-moprolol has shown a remarkable hypotonic effect without showing any appreciable local or systemic side

effect.

The pharmaceutical preparations useful to the purpose are those commonly used in the ophthalmic field such as, for example, collyria or ointments.

5 These preparations contain a suitable amount of l-moprolol or of a pharmaceutically acceptable acid addition salt thereof together with diluents, preservatives, buffers, stabilizers etc. commonly used by the artisan. In addition, they may be ready for the use or prepared extemporaneously.

10 Preferably these preparations contain a quantity of 1-moprolol ranging from 0.1 to 20%; still more preferred forms are those containing from 1 to 8% of 1-moprolol.

Examples of suitable pharmaceutical forms are:

- | | | | | |
|----|------------|----|-----------------|---------|
| 15 | 1. Powder: | a) | l-moprolol | 0.100 g |
| | | | sodium chloride | 0.060 g |
| | | b) | l-moprolol | 0.200 g |
| | | | sodium chloride | 0.030 g |

each of the above powders is taken up, at the time of use, with the following

- 20 Solvent: benzalkonium chloride 0.001 g - disodium EDTA 0.001 g
- disodium phosphate $12H_2O$ 0.0243 g - monosodium
phosphate H_2O 0.0074 g - distilled water q.s. to 10
ml.

2. Solution

- | | | |
|----|------------------------------------|----------------|
| 25 | l-moprolol (as hydrochloride salt) | 0.500 g |
| | sodium chloride | 0.880 |
| | benzalkonium chloride | 0.010 |
| | monosodium phosphate monohydrate | 0.180 |
| | disodium phosphate dihydrate | 0.220 |
| 30 | distilled water | q.s. to 100 ml |

3. Solution

	1-moprolol (as hydrochloride salt)	4.00 g
	sodium chloride	0.030 g
	benzalkonium chloride	0.010 g
5	monosodium phosphate monohydrate	0.180 g
	disodium phosphate dihydrate	0.220 g
	distilled water	q.s. to 100 ml

4. Ointment

	1-moprolol (as hydrochloride salt)	1.00 g
10	paraffin oil	25.50 g
	White vaseline	73.50 g

The pharmacological activity of these collyria has been tested as follows:

- experimental animal: rabbit;
- 15 - measurement of intraocular pressure by an electronic tonometer (Mackay-Marg) after local anesthesia with 0.4% Novesine Wander;
- experimentally induced hypertension: introduction in the anterior chamber of powder of *Laminaria digitata* (Priestley et al., Bollettino di Oculista, 47, (10), (1968), 652-668);
- 20 - measurement of systemic arterial pressure: after isolation under local anesthesia with 1% Sclerocaine, the femoral artery was cannulated by a polyvinyl catheter and the system connected with an electromanometer (Telco Thomson) and with a
- 25 Varian C -2000 apparatus to record continuously and graphically the arterial pressure;
- measurement of vasomotor activity on the ciliary body by a technique based on the indirect evaluation of the ciliary permeability after paracentesis (Virno et al., Bollettino di
- 30 Oculistica, 58, (1982), Supplemento al N. 11-12);

0118940

The results of the above mentioned tests have been the followings:

- 1-moprolol exhibits a remarkable hypotensive effect either on the normal eye (Fig. 1) or, particularly, on the eye with experimentally induced ocular hypertension (Fig. 2);
- the biomicroscopic examination did not show significant alterations of cornea and conjunctiva neither after single instillation or after administration twice a day for 30 days;
- the instillation of the drug did not cause systemic effects;
- the intravenous administration caused a reduction of the intraocular pressure concomitant with the systemic hypotension, which means a passive participation of the intraocular circulation to the general vascular phenomenon (Fig. 3);
- the instillation of the compound under examination caused a response of the ciliary body which resulted in a vasodilatation when was lacking the extracirculatory pressure whereas when this pressure was present the vasodilatation phenomenon has been reversed in a "passive" vasoconstriction with concomitant reduction of the vasal permeability and of the production of aqueous humour (Virno et al., Bollettino di oculistica, 58, (1982), Suppl.to No. 11-12) (Fig. 4);
- the tachyphylaxis evaluation showed that the amount of the intra-ocular hypotensive response is not reduced during the period of treatment (30 days) (Fig. 5)

The above mentioned properties have been confirmed in humans; 20 patients suffering from simple cronic glaucoma have been treated 2-3 times a day with 1/2 drops (0.5/1 mg) of collyrium containing 1% 1-moprolol. Treatment caused reduction of the intraocular pressure and the preparation resulted very well tolerated: no evidence of burnings or of side effects on the

cornea. No heart rate or arterial pressure variation has been observed (Fig. 7).

CLAIMS

1. An ophthalmic pharmaceutical composition for treating glaucoma comprising an effective amount of l-moprolol or of a pharmaceutically acceptable acid addition salt thereof.

5 2. An ophthalmic pharmaceutical composition according to claim 1, comprising from 1 to 8% of l-moprolol.

3. A process for treating glaucoma comprising administering locally from 0.5 to 6 mg of l-moprolol per day.

10 4. A process according to claim 3, where the daily administrations range from 1 to 4.

1/4

0118940

Figure 1





Figure 2



2/2

0118940

Figure 3





Figure 4



VASOMOTOR ACTIVITY OF 1-MOPROLOL ON CILIARY CIRCULATION EVALUATED THROUGH THE ALTERATION OF THE BLOOD/AQUEOUS HUMOUR BARRIER PERMEABILITY

Figure 5




Figure 6





Figure 7





DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
X	BE-A- 678 902 (SHELL) * Page 4, claims *	1	A 61 K 31/13
X	US-A-4 303 637 (J.W. SHELL et al.) * Claims *	1-4	
A	US-A-4 342 783 (P.L. MORSELLI et al.) * Claims *	1-4	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
			A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 18-05-1984	Examiner MOREAU J.M.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO Form 1503, 03.82

THIS PAGE LEFT BLANK

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

